We've changed the way you complete courses

In response to user feedback we have simplified the way courses can be completed.

Until now you needed to complete the topics and modules in order, from start to finish. But from today you can complete them in any order you wish.

Just visit any topic that interests you, and when you are ready mark it as completed by clicking the green 'Mark complete' button at the bottom of the page.

Once you have completed all of the topics in a module an assessment will be provided for you.

Complete all the assessments to finish the course.

Thanks, I've got it! X

Select image for larger view
These data come from studies with anti-CD3 antibodies like otelixizumab or teplizumab. Here it could be demonstrated that, again, either with an open comparator arm, or with a control group, like in the otelixizumab studies, it could be shown that, for at least six months, one had a preservation of functional beta cell mass, with only a one or two weeks duration of the anti-CD3 antibody treatment. But then we have to agree that, after six months, the loss of beta cells mass starts again.
Play the audio to learn more

Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002 May 30;346(22):1692-8.
http://www.ncbi.nlm.nih.gov/pubmed/12037148

Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 2005 Jun;54(6):1763-9.
http://www.ncbi.nlm.nih.gov/pubmed/15919798